Anna Ågren

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Forskningsbeskrivning

Dr Anna Ågren MD, PhD is associate professor in Medicine. She is a Senior Consultant at the Coagulation Unit. Hematology Center. Her research interests are bleeding disorders and thrombotic diseases.

She is supervisor and co-supervisor to PhD students with main focus on coagulopathy in critical illness, von Willebrand disease, endothelial function and fibrinolysis in obesity and measurements of global hemostasis in patients with oral anticoagulant treatment and hemophilia.

Artiklar

Article: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2025;110(10):e3193-e3202
Influence of Bariatric Surgery on Endothelial and Glycocalyx Biomarkers in Obesity and Type 2 Diabetes
Andersson M; Agren A; Henriksson P; Wallen H; Thorell A
Article: HAEMOPHILIA. 2025;31(3):450-457
Ratio of Von Willebrand Collagen Binding Assay and Von Willebrand Antigen Can Predict Multimer Size in Von Willebrand Disease
Kimiaei A; Pruner I; Farm M; Holmstrom M; Karandyszowska N; Bruzelius M; Antovic J; Agren A
Article: THROMBOSIS RESEARCH. 2024;243:109135
Tocilizumab reduces hypercoagulation in COVID-19-Perspectives from the coagulation and immunomodulation Covid assessment (Coag-ImmCovA) clinical trial
Almskog LM; Sjostrom A; Sunden-Cullberg J; Taxiarchis A; Agren A; Freyland S; Borjesson M; Wikman A; Wahlgren CM; Wanecek M; van der Linden J; Antovic J; Lampa J; Magnusson M
Article: ACTA NEUROCHIRURGICA. 2024;166(1):385
Anticoagulation strategies in patients with coexisting traumatic intracranial hematomas and cerebral venous sinus thrombosis: an observational cohort study
Antonsson J; Tatter C; Agren A; Alpkvist P; Thelin EP; Fletcher-Sandersjoo A
Article: EJHAEM. 2024;5(4):768-771
Iatrogenic hemorrhage and extensive venous thromboembolism during iTTP treatment with caplacizumab-A case report
Boberg E; Kimiaei A; Karlstrom C; Ljungqvist M; Agren A; Bruzelius M
Article: SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION. 2024;84(4):257-267
Effects of dabigatran, rivaroxaban, and apixaban on fibrin network permeability, thrombin generation, and fibrinolysis
Taune VS; Zabczyk M; He S; Agren A; Blomback M; Wallen H; Skeppholm M
Article: LAKARTIDNINGEN. 2023;120:22151
Livshotande trombotisering efter missbruk av stor mängd lustgas.
J Siddiqui A; Gautam G; Ågren A; Nordmark Grass J
Article: PLOS ONE. 2022;17(10):e0276775
Fibrinogen and albumin synthesis rates in major upper abdominal surgery
Dumitrescu G; Januszkiewicz A; Agren A; Magnusson M; Sparrelid E; Rooyackers O; Wernerman J
Article: INTERNATIONAL UROLOGY AND NEPHROLOGY. 2022;54(10):2695-2702
Platelet thrombus formation in patients with end-stage renal disease before and after hemodialysis as measured by the total thrombus-formation analysis system
Mitic BP; Dimitrijevic ZM; Hosokawa K; Cvetkovic TP; Lazarevic MV; Tasic DD; Jovanovic A; Jancic N; Vrecic T; Agren A; Wallen H
Article: TH OPEN. 2022;06(03):e238-e247
Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop
Taune V; Skeppholm M; Agren A; Wikman A; Hillarp A; Wallen H
Article: TH OPEN. 2022;06(01):e50-e59
Hypercoagulation Detected by Rotational Thromboelastometry Predicts Mortality in COVID-19: A Risk Model Based on a Prospective Observational Study
Almskog LM; Wikman A; Svensson J; Bottai M; Kotorman M; Wahlgren C-M; Wanecek M; van der Linden J; Agren A
Article: THROMBOSIS AND HAEMOSTASIS. 2021;121(12):1610-1621
Platelet Count Rose While D-Dimer Levels Dropped as Deaths and Thrombosis Declined-An Observational Study on Anticoagulation Shift in COVID-19
Sjostrom A; Wersall JD; Warnqvist A; Farm M; Magnusson M; Oldner A; Agren A; Antovic J; Bruzelius M
Article: SCIENTIFIC REPORTS. 2021;11(1):18025
Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma
Zenlander R; Havervall S; Magnusson M; Engstrand J; Agren A; Thalin C; Stal P
Article: JOURNAL OF THROMBOSIS AND THROMBOLYSIS. 2021;51(2):437-445
Rotational thromboelastometry results are associated with care level in COVID-19
Almskog LM; Wikman A; Svensson J; Wanecek M; Bottai M; van der Linden J; Agren A
Article: CRITICAL CARE EXPLORATIONS. 2020;2(12):e0308
Thromboembolism, Hypercoagulopathy, and Antiphospholipid Antibodies in Critically Ill Coronavirus Disease 2019 Patients: A Before and After Study of Enhanced Anticoagulation.
van der Linden J; Almskog L; Liliequist A; Grip J; Fux T; Rysz S; Ågren A; Oldner A; Ståhlberg M
Journal article: THROMBOSIS RESEARCH. 2020;194:98-100
Results of in vitro whole blood coagulation assays using ROTEM and the flow-chamber T-TAS system are affected by hematocrit
Agren A; Edgren G; Hjemdahl P; Gryfelt G; Ostlund A; Wikman A
Article: SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE. 2020;28(1):5
A retrospective register study comparing fibrinogen treated trauma patients with an injury severity score matched control group
Almskog LM; Hammar U; Wikman A; Ostlund A; Svensson J; Wanecek M; Agren A
Article: THROMBOSIS RESEARCH. 2019;178:34-40
Correlation of thromboelastography and thrombin generation assays in warfarin-treated patients
Schmidt DE; Chaireti R; Bruzelius M; Holmstrom M; Antovic J; Agren A
Article: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2018;16(12):2462-2470
Rapid determination of anticoagulating effects of dabigatran in whole blood with rotational thromboelastometry and a thrombin-based trigger
Taune V; Skeppholm M; Agren A; Gryfelt G; Malmstrom RE; Wikman A; Van Ryn J; Wallen H
Article: BLOOD. 2017;130(15):1706-1712
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study
Majeed A; Agren A; Holmstrom M; Bruzelius M; Chaireti R; Odeberg J; Hempel E-L; Magnusson M; Frisk T; Schulman S
Article: THROMBOSIS RESEARCH. 2017;158:168-173
Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS)
Grosso G; Vikerfors A; Woodhams B; Adam M; Bremme K; Holmstrom M; Agren A; Eelde A; Bruzelius M; Svenungsson E; Antovic A
Article: SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION. 2017;77(6):397-405
Relative effects of plasma, fibrinogen concentrate, and factor XIII on ROTEM coagulation profiles in an in vitro model of massive transfusion in trauma
Schmidt DE; Halmin M; Wikman A; Ostlund A; Agren A
Article: THROMBOSIS AND HAEMOSTASIS. 2017;117(8):1528-1533
Whole blood ristocetin-activated platelet impedance aggregometry (Multiplate) for the rapid detection of Von Willebrand disease
Schmidt DE; Bruzelius M; Majeed A; Odeberg J; Holmstrom M; Agren A
Article: MEDICINE. 2017;96(23):e7101
Thromboelastometry: Relation to the severity of liver cirrhosis in patients considered for liver transplantation
Dumitrescu G; Januszkiewicz A; Agren A; Magnusson M; Wahlin S; Wernerman J
Article: THROMBOSIS RESEARCH. 2017;153:76-82
Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment
Taune V; Wallen H; Agren A; Gryfelt G; Sjovik C; Wintler AM; Malmstrom RE; Wikman A; Skeppholm M
Article: HAEMOPHILIA. 2017;23(2):309-318
A prospective diagnostic accuracy study evaluating rotational thromboelastometry and thromboelastography in 100 patients with von Willebrand disease
Schmidt DE; Majeed A; Bruzelius M; Odeberg J; Holmstrom M; Agren A
Article: THROMBOSIS AND HAEMOSTASIS. 2017;117(1):75-85
Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system
Agren A; Holmstrom M; Schmidt DE; Hosokawa K; Blomback M; Hjemdahl P
Article: BLOOD COAGULATION & FIBRINOLYSIS. 2016;27(3):334-339
Haemostasis monitored in stored red blood cells, plasma and platelet concentrates in the proportion of 4: 4: 1 diluted with crystalloids and colloids
Agren A; Edgren G; Ambrosio D; Gryfelt G; Ostlund A; Wikman A
Article: JOURNAL OF THROMBOSIS AND THROMBOLYSIS. 2015;40(4):430-436
Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves
Schulman JM; Majeed A; Mattsson E; Schulman S; Holmstrom M; Agren A
Article: THROMBOSIS RESEARCH. 2015;136(2):402-407
The temporal pattern of postoperative coagulation status in patients undergoing major liver surgery
Dumitrescu G; Januszkiewicz A; Agren A; Magnusson M; Isaksson B; Wernerman J
Article: THROMBOSIS RESEARCH. 2015;135(5):1007-1011
Detection of elevated INR by thromboelastometry and thromboelastography in warfarin treated patients and healthy controls
Schmidt DE; Holmstrom M; Majeed A; Naslin D; Wallen H; Agren A
Article: THROMBOSIS AND HAEMOSTASIS. 2015;113(2):312-318
Fibrin clot properties and haemostatic function in men and women with type 1 diabetes
Tehrani S; Jorneskog G; Agren A; Lins P-E; Wallen H; Antovic A
Journal article: ANESTHESIA AND ANALGESIA. 2014;119(6):1453
Viscoelastic Test and Fibrinogen Values: How Much Disagreement Is Permissible? Response
Agren A; Wikman A; Ostlund A; Edgren G
Journal article: DIABETES CARE. 2014;37(11):e244
Increased Incorporation of Antiplasmin Into the Fibrin Network in Patients With Type 1 Diabetes. Diabetes Care 2014; 37: 2007-2014
Agren A; Jorneskog G; Elgue G; Henriksson P; Wallen H; Wiman B
Article: BLOOD TRANSFUSION. 2014;12(4):491-496
In vitro combinations of red blood cell, plasma and platelet components evaluated by thromboelastography
Agren A; Edgren G; Kardell M; Ostlund A; Wikman AT
Article: DIABETES CARE. 2014;37(7):2007-2014
Increased Incorporation of Antiplasmin Into the Fibrin Network in Patients With Type 1 Diabetes
Agren A; Jorneskog G; Elgue G; Henriksson P; Wallen H; Wiman B
Article: ANESTHESIA AND ANALGESIA. 2014;118(5):933-935
TEGr Functional Fibrinogen Analysis May Overestimate Fibrinogen Levels
Agren A; Wikman AT; Ostlund A; Edgren G
Article: THROMBOSIS RESEARCH. 2014;133(5):936-944
Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome
Vikerfors A; Svenungsson E; Agren A; Mobarrez F; Bremme K; Holmstrom M; Eelde A; Bruzelius M; Elgue G; Wallen H; Antovic A
Article: SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION. 2013;73(3):214-220
Thromboelastography (TEG®) compared to conventional coagulation tests in surgical patients - a laboratory evaluation
Agren A; Wikman AT; Holmstrom M; Ostlund A; Edgren G
Article: LUPUS. 2012;21(7):802-805
Studies of microparticles in patients with the antiphospholipid syndrome (APS)
Vikerfors A; Mobarrez F; Bremme K; Holmstrom M; Agren A; Eelde A; Bruzelius M; Antovic A; Wallen H; Svenungsson E
Journal article: THROMBOSIS RESEARCH. 2012;129(5):668-670
A case series of five episodes of massive LMWH non-fatal self-induced overdose in a single patient
Odeberg J; Carlsson A; Hallsjo-Sander C; Agren A
Article: THROMBOSIS RESEARCH. 2012;129(2):146-151
Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy
Majeed A; Eelde A; Agren A; Schulman S; Holmstrom M
Article: LAKARTIDNINGEN. 2011;108(3):92-95
[Life-saving transplantation in pregnancy-related liver failure. Well functioning care continuity contributed to the good result].
Agren A; Stål P; Agvald-Ohman C; Eleborg L; Nowak G; Ajne G
Article: JOURNAL OF INTERNAL MEDICINE. 2008;264(6):586-592
Low PAI-1 activity in relation to inflammatory parameters, insulin profile and body mass index
Agren A; Wiman B; Schulman S
Article: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2008;6(8):1313-1318
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.
Botticelli Investigators, Writing Committe; Buller H; Deitchman D; Prins M; Segers A
Article: LAKARTIDNINGEN. 2007;104(48):3640-3642
["Triple therapy" with warfarin, clopidogrel and acetylsalicylic acid. High risk treatment with unclear benefit].
Wallén H; Agren A; Nekludov M
Article: BLOOD COAGULATION & FIBRINOLYSIS. 2007;18(7):657-660
Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity
Agren A; Wiman B; Schulman S
Article: THROMBOSIS RESEARCH. 2007;119(6):715-721
Low PAI-1 activity in relation to the risk for perioperative bleeding complications in transurethral resection of the prostate
Agren A; Kolmert T; Wiman B; Schulman S
Article: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2006;4(1):201-208
Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis
Ågren A; Wiman B; Stiller V; Lindmarker P; Sten-Linder M; Carlsson A; Holmström M; Odeberg J; Schulman S
Visa fler

Alla övriga publikationer

Review: FRONTIERS IN IMMUNOLOGY. 2025;16:1599639
Thromboinflammation vs. immunothrombosis: strategies for overcoming anticoagulant resistance in COVID-19 and other hyperinflammatory diseases. Is ROTEM helpful or not?
Almskog LM; Agren A
Other: JACC: CASE REPORTS. 2024;29(9):102312
Life-Threatening Thrombosis After Large Amounts of Nitrous Oxide Use.
McMahon G; Lönnberg F; Gautam G; Ågren A; Nordmark Grass J; Siddiqui AJ
Published conference paper: HAEMOPHILIA. 2018;24:5-19
Fifth Aland Island conference on von Willebrand disease
Berntorp E; Agren A; Aledort L; Blomback M; Cnossen MH; Croteau SE; von Depka M; Federici AB; Goodeve A; Goudemand J; Mannucci PM; Mourik M; Onundarson PT; Rodeghiero F; Szanto T; Windyga J
Other: LAKARTIDNINGEN. 2018;115:EYWT
Tilltagande anemi och trombocytopeni hos gravida kan vara trombotisk trombocytopen purpura.
Ågren A; Antovic J; Strandberg K; Frisk T; Löfstedt P; Strindfors G; Celsing F
Review: LAKARTIDNINGEN. 2015;112:DCPM
[Sickle cell anemia causes varied symptoms and high morbidity. Serious prognosis in the most common genetic disease in the world].
Kjellander C; Sennström MKB; Stiller V; Ågren A
Meeting abstract: THROMBOSIS RESEARCH. 2013;131:S72
Gender aspects of fibrin clot structure in patients with type 1 diabetes mellitus
Tehrani S; Wallen NH; Elgue G; Majeed K; Henriksson P; Agren A; Adamson U; Lins P-E; Jorneskog G; Antovic A
Meeting abstract: THROMBOSIS RESEARCH. 2012;130:S122
Does a tight fibrin clot in premenopausal women with type 1 diabetes explain the lack of gender difference in cardiovascular disease?
Antovic A; Wallen NH; Elgue G; Majeed K; Henriksson P; Agren A; Adamson U; Lins P-E; Jorneskog G
Doctoral thesis: 2008
Mechanisms and effects of low plasminogen activator inhibitor type 1 activity
Ågren A

Anställningar

Anknuten till Forskning, Kliniska vetenskaper, Danderyds sjukhus, Karolinska Institutet, 2024-2027
Anknuten till Forskning, Molekylär medicin och kirurgi, Karolinska Institutet, 2023-2026

Examina och utbildning

Docent, medicin, Karolinska Institutet, 2017
Medicine Doktorsexamen, Institutionen för medicin, Solna, Karolinska Institutet, 2008

Forskningsbeskrivning

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI